Research collaboration including to optimize and develop CAR T cell processing procedures. We have been working closely with City of Hope since January 2018.
Broad collaboration including developing and optimizing processes and systems associated with cell processing, licensing agreements allowing coordinated use of CAR T therapies, and collaborating funding agreements.
Broad collaboration including developing and optimizing processes and systems associated with cell processing, licensing agreements allowing coordinated use of CAR T therapies, and collaborating funding agreements.
Mayo Clinic entered into a technology development and licensing collaboration with Mustang Bio, a clinical-stage biopharmaceutical company, to develop a novel cell therapy technology to transform the administration of chimeric antigen receptor engineered T cell (“CAR T”) therapies to potentially be used as an off-the-shelf therapy.
A worldwide licensing agreement to develop an oncolytic virus (C134) for glioblastoma multiforme, an aggressive form of brain cancer that has an incidence of two to three per 100,000 adults per year, and accounts for 52 percent of all primary brain tumors. A Phase 1 clinical trial for MB-108 is scheduled to commence in the first half of 2019.
Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency